Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer

Vγ9Vδ2 T cells are promising candidates for cellular tumor immunotherapy. Due to their HLA-independent mode of action, allogeneic Vγ9Vδ2 T cells can be considered for clinical application. To apply allogeneic Vγ9Vδ2 T cells in adoptive immunotherapy, the methodology used to obtain adequate cell numb...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Yan, Xiang, Zheng, Alnaggar, Mohammed, Kouakanou, Léonce, Li, Jiawei, He, Junyi, Yang, Jiashuang, Hu, Yi, Chen, Yan, Lin, Li, Hao, Jianlei, Li, Jingxia, Chen, Jibing, Li, Man, Wu, Qingling, Peters, Christian, Zhou, Qinghua, Li, Jianshuang, Liang, Yingqing, Wang, Xiaohua, Han, Baohui, Ma, Meili, Kabelitz, Dieter, Xu, Kecheng, Tu, Wenwei, Wu, Yangzhe, Yin, Zhinan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8027668/
https://www.ncbi.nlm.nih.gov/pubmed/32939032
http://dx.doi.org/10.1038/s41423-020-0515-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8027668/
https://www.ncbi.nlm.nih.gov/pubmed/32939032
http://dx.doi.org/10.1038/s41423-020-0515-7

Ejemplares similares